September 14, 2020
Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange
Read More
September 11, 2020
Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA
Read More
September 10, 2020
Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC
Read More
August 14, 2020
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021
Read More
August 13, 2020
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
Read More
August 11, 2020
Appili Therapeutics Receives Eligibility for DTC Trading in the U.S
Read More
August 10, 2020
FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities
Read More
July 30, 2020
Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19
Read More
June 24, 2020
Appili Therapeutics Announces FY 2020 Annual and Financial Results
Read More
June 15, 2020
Appili Therapeutics Commences Trading on the OTCQX Marketplace
Read More
June 10, 2020
Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000
Read More
June 5, 2020
Appili Therapeutics Announces Filing of Prospectus Supplement and Proposed Concurrent Private Placement
Read More
June 4, 2020
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering in June 2020
Read More
June 3, 2020
Appili Therapeutics Announces Overnight Marketed Equity Offering
Read More
May 21, 2020
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
Read More
May 11, 2020
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities
Read More
May 4, 2020
Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference
Read More
April 21, 2020
Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer
Read More
February 27, 2020
Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020 Copy
Read More
February 20, 2020
Appili Therapeutics Announces Closing of Public Offering of $10,250,000
Read More